Alpha 2.0
Login Register
» Articles » PMID: 22834568

Transdermal Granisetron: a Guide to Its Use in Preventing Nausea and Vomiting Induced by Chemotherapy

Overview
Journal CNS Drugs
Specialties Neurology
Pharmacology
Date 2012 Jul 28
PMID 22834568
Citations 5
Authors
Gillian M Keating
Sean T Duggan
Monique P Curran
Affiliations
Soon will be listed here.
Abstract

Transdermal granisetron (Sancuso®) is effective in the prevention of nausea and vomiting in patients with cancer who are receiving moderately or highly emetogenic chemotherapy for 3-5 days. Transdermal granisetron is noninferior to oral granisetron in this indication, and is generally well tolerated in this indication. Thus, transdermal granisetron provides a convenient option for the prevention of chemotherapy-induced nausea and vomiting, with the potential to improve patient compliance.

Citing Articles

Population pharmacokinetic analysis of transdermal granisetron in healthy Chinese and Caucasian volunteers.

Li J, Hu P, Zhou L, Nagahama F, Chen R Front Pharmacol. 2023; 14:1154026.

PMID: 37435499 PMC: 10330959. DOI: 10.3389/fphar.2023.1154026.

Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study.

Midani D, Parkman H J Neurogastroenterol Motil. 2016; 22(4):650-655.

PMID: 27400689 PMC: 5056574. DOI: 10.5056/jnm15203.

Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant-palonosetron combination.

Janicki P Ther Clin Risk Manag. 2016; 12:693-9.

PMID: 27194913 PMC: 4859423. DOI: 10.2147/TCRM.S81126.

A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.

Kim J, Hong Y, Lee J, Kim K, Park S, Sym S Support Care Cancer. 2014; 23(6):1769-77.

PMID: 25465680 DOI: 10.1007/s00520-014-2507-6.

Granisetron transdermal system improves refractory nausea and vomiting in gastroparesis.

Simmons K, Parkman H Dig Dis Sci. 2014; 59(6):1231-4.

PMID: 24615549 DOI: 10.1007/s10620-014-3097-3.

References
1.
Plosker G, Goa K . Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic. Drugs. 1991; 42(5):805-24. DOI: 10.2165/00003495-199142050-00007. View
2.
Hesketh P . Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008; 358(23):2482-94. DOI: 10.1056/NEJMra0706547. View
3.
Boccia R, Gordan L, Clark G, Howell J, Grunberg S . Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2010; 19(10):1609-17. PMC: 3166600. DOI: 10.1007/s00520-010-0990-y. View
4.
Navari R . Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs. 2009; 69(5):515-33. DOI: 10.2165/00003495-200969050-00002. View
5.
Lohr L . Chemotherapy-induced nausea and vomiting. Cancer J. 2008; 14(2):85-93. DOI: 10.1097/PPO.0b013e31816a0f07. View